Prostate and bladder cancers affect millions of patients globally, yet validated biomarkers that can reliably predict treatment response, disease progression, and therapy resistance remain scarce in clinical practice. BRECISE seeks to change this by integrating cutting-edge technologies such as Next-Generation Sequencing (NGS), Artificial Intelligence (AI), and ex vivo drug testing to refine personalized treatment pathways.

BRECISE is structured around four core objectives: Clinical Validation of Biomarkers, Integration of NGS and AI, Ex Vivo Tumour Testing and Regulatory and Market Adoption.

The objective of Doctoral Networks is to implement doctoral programs by partnerships of organizations from different sectors across Europe and beyond to train highly skilled doctoral candidates, stimulate their creativity, enhance their innovation capacities and boost their employability in the long-term.

The SIGNATURE MSCA Doctoral network aims to elucidate the mechanisms of disease progression and therapeutic responses of autoimmune disorders such as systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, asthma, chronic obstructive pulmonary disease, Crohn´s disease and ulcerative colitis.

Treatment with neoadjuvant chemotherapy plus immunotherapy (CH-I) is of key importance for the treatment of patients with locally advanced and metastatic NMSC. However, we lack biomarkers capable of discriminating between patients who benefit from the CH-I combination and those who do not.

The main objective of the project is to obtain a new tool for stratifying the risk of relapse/progression in patients with microcytic lung cancer treated with chemoimmunotherapy using new molecular biomarkers.

The usual treatment for breast cancer consists of surgery and radiation therapy to slow the progression of the disease in the breast, lymph nodes, and surrounding areas, and systemic therapy to treat and/or reduce the risk of cancer spread. Radiotherapy can be used at almost all stages, and this treatment is an effective way to reduce the risk of recurrence after surgery. However, radiation to the breast can cause acute side effects, reversible in the short term, and delayed side effects, which are essentially in the form of breast fibrosis. For this reason, it is necessary to investigate and develop a reproducible assay that makes it possible to predict the individual radiosensitivity of normal tissues on radiotherapy.

The objective of the project is to develop a multiparametric predictive molecular signature capable of identifying the toxicity derived from radiotherapy in women with breast cancer. The values of different biomarkers and clinical parameters will be compared in a trial cohort, selecting those that make it possible to differentiate patients who develop adverse effects from those who do not, and then a validation cohort will be analysed.